SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001641489-23-000019
Filing Date
2023-05-11
Accepted
2023-05-11 16:06:14
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20230511.htm   iXBRL 8-K 34550
2 EX-99.1 vtvt-20230331xexx991pressr.htm EX-99.1 77531
6 vtvv_outlinexcolorxnotaglia.jpg GRAPHIC 116073
  Complete submission text file 0001641489-23-000019.txt   409704

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20230511.xsd EX-101.SCH 1911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20230511_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20230511_pre.xml EX-101.PRE 12514
8 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20230511_htm.xml XML 11394
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

IRS No.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 23910955
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences